NCT00600548 - Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

July 31, 2009

Conditions

Treatment of Cutaneous Leishmaniasis in Brazil.

Interventions

DRUG

Miltefosine.

Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.

DRUG

Meglumine antimoniate.

Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.

DRUG

Miltefosine.

Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.

DRUG

Meglumine antimoniate.

Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.

Trial Locations (2)

Fundação de Medicina Tropical do Amazonas, Manaus

Posto de Saúde de Corte de Pedra, Tancredo Neto